1788.TWO Hi-Clearance
- Market cap
- TWD 5.61B
- P/E
- 14.3x
- P/B
- 1.91x
- ROE
- 14.0%
- Dividend yield
- 5.56%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 1788.TWO undervalued?
Graham number1788.TWO trades 10.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hi-Clearance fundamental analysis
No fundamental analysis for Hi-Clearance yet.
Hi-Clearance stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hi-Clearance
Hi-Clearance Inc. supplies medical devices for the renal, cardiac, radiation, dentistry, oral surgery, thoracic, respiratory, and metabolism markets in Taiwan. The company offers dialyzers, dialysis and, RO machines, and related consumables and drugs; interventional cardiology and radiology, and plastic surgery devices; dentistry consumables, implant materials, and equipment; and blood glucose monitors, and related consumables and nutrition products, as well as hemodialysis …
Full company profileHi-Clearance financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hi-Clearance annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.83B | 2.96B | 3.10B | 3.24B | 3.43B | 3.68B | 4.69B | 3.90B | 4.07B | 4.28B | 4.51B |
| Gross Profit | 597M | 669M | 684M | 736M | 849M | 969M | 1.05B | 1.02B | 1.07B | 1.14B | 1.28B |
| Operating Income | 242M | 272M | 297M | 328M | 400M | 447M | 470M | 415M | 428M | 422M | 504M |
| EBITDA | - | 338M | 349M | 434M | 531M | 598M | 631M | 612M | 648M | 673M | 738M |
| Net Income | 208M | 251M | 243M | 246M | 317M | 349M | 366M | 348M | 360M | 369M | 412M |
| EPS | - | 7.14 | 6.93 | 6.31 | 7.76 | 8.50 | 8.94 | 7.82 | 8.08 | 8.28 | 9.26 |
| Balance Sheet | |||||||||||
| Total Assets | 2.47B | 2.61B | 2.97B | 3.73B | 4.20B | 4.44B | 4.51B | 4.62B | 4.96B | 5.08B | 5.29B |
| Total Liabilities | 913M | 988M | 1.33B | 1.94B | 2.19B | 2.13B | 2.07B | 1.63B | 1.96B | 2.03B | 2.34B |
| Shareholders' Equity | 1.56B | 1.63B | 1.64B | 1.78B | 2.01B | 2.30B | 2.44B | 2.98B | 3.00B | 3.05B | 2.95B |
| Cash & Short-term Investments | 295M | 282M | 286M | 554M | 474M | 405M | 417M | 401M | 415M | 464M | 437M |
| Total Debt | - | - | - | 1.08B | 1.26B | 1.14B | 1.04B | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 328M | 243M | 314M | 257M | 413M | 288M | 403M | 433M | 510M | 390M | 159M |
| Capital Expenditure | 8.99M | 111M | 269M | 38.3M | 232M | 151M | 103M | 64.3M | 285M | 111M | 87.7M |
| Free Cash Flow | - | 132M | 45.6M | 218M | 181M | 137M | 300M | 369M | 226M | 278M | 70.8M |
| Ratios | |||||||||||
| ROE | 13.3% | 15.5% | 14.8% | 13.8% | 15.8% | 15.1% | 15.0% | 11.7% | 12.0% | 12.1% | 14.0% |
| ROA | 8.4% | 9.6% | 8.2% | 6.6% | 7.5% | 7.9% | 8.1% | 7.5% | 7.3% | 7.2% | 7.8% |
| Net Profit Margin | 7.3% | 8.5% | 7.9% | 7.6% | 9.2% | 9.5% | 7.8% | 8.9% | 8.8% | 8.6% | 9.2% |
| Debt to Equity | - | - | - | 0.60x | 0.62x | 0.50x | 0.43x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hi-Clearance dividends
- Dividend yield
- 5.56%
- Forward dividend
- 7.00 TWD
- Payout ratio
- 84.6%
- Ex-dividend date
- Jun 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 312M | 7.00 | 84.6% |
| 2024 | TWD 312M | 7.00 | 86.6% |
| 2023 | TWD 312M | 7.00 | 89.6% |
| 2022 | TWD 284M | 6.92 | 77.4% |
| 2021 | TWD 263M | 6.42 | 75.5% |
| 2020 | TWD 216M | 5.28 | 68.1% |
| 2019 | TWD 216M | 5.54 | 87.9% |
| 2018 | TWD 210M | 5.97 | 86.3% |
| 2017 | TWD 175M | 4.98 | 69.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Hi-Clearance
- Insiders 54.96%
- Institutions 9.96%
- Public & others 35.08%
- Shares outstanding 44.5M
- Free float 25.3M
Hi-Clearance company profile
- Company name
- Hi-Clearance
- Ticker
- 1788.TWO
- ISIN
- TW0001788008
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- No. 2, Chongxin Road, New Taipei City, Taiwan, 24159
- Phone
- 886 2 2995 3318
- Website
- hiclearance.com.tw
About Hi-Clearance
Hi-Clearance Inc. supplies medical devices for the renal, cardiac, radiation, dentistry, oral surgery, thoracic, respiratory, and metabolism markets in Taiwan. The company offers dialyzers, dialysis and, RO machines, and related consumables and drugs; interventional cardiology and radiology, and plastic surgery devices; dentistry consumables, implant materials, and equipment; and blood glucose monitors, and related consumables and nutrition products, as well as hemodialysis management services. It engages in the design and management of dialysis centers; and sale and service of healthy and natural drinks, as well as operates as an OEM supplier for beverage raw materials and concentrates. Hi-Clearance Inc. was founded in 1989 and is headquartered in New Taipei City, Taiwan.
Hi-Clearance management
2- Mr. Kuo-Shih ChenManager
- Yaw-Yuan ChangChief Accountant